Reuters Stock Buzz Powered by SocialPicks Logo_divider Logo_thomsonreuters Bg_dots_d1
   Sign Up   |   Log In   |   What is Reuters Stock Buzz?   |   FAQ powered by Logo_powered_by_socialpicks

Important Message: The Reuters Stock Buzz beta period will end Friday, October 31. If you would like to continue to access your Stock Buzz account through SocialPicks, please click here

 Pressure BioSciences Inc.  (PBIO)     Rate PBIO  -  Discuss PBIO  -  Add to Watch List         Graphic_subscribe

       Sector: Healthcare  >  Industry: Biotechnology & Drugs
SocialPicks Sentiment:
N/A

** not enough data to be rated 		This Quarter's Sentiment:
All:
20.0%
Top:
0.0%
Rate PBIO:


Home
Quotes
Bull or Bear
Who's Rated PBIO
Discuss
        

PBIO: Bull or Bear?


Foto
-4.25%
 risk: low
Pressure BioSciences Inc.  07/03/08
Pressure BioSciences, Inc., a life sciences company, engages in the research, development, and commercialization of pressure cycling technology (PCT) that uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The company offers Barocycler instrumentation, which includes Barocycler NEP3229 that is capable of processing up to three samples si...

Blog_photo
-14.05%
 risk: low
Pressure BioSciences Inc. (PBIO) Hires Matthew Potter to Join Management Team as the Vice President of Sales  03/12/08
Today Pressure BioSciences Incorporated announced that it has added a new member to its senior executive management team; Vice President of Sales. Matthew B. Potter will now oversee Pressure Biosciences’ seven US-based, regional sales directors and will be responsible for driving the Company’s commercialization of their novel and patented pressure cycling technology (PCT) product line. ...

Blog_photo
-14.05%
 risk: low
Pressure Biosciences, Inc. (PBIO) - Equipped with Product Line to Fight Disease  03/06/08
Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics, proteomics and nucleic acid testing with the ability to ru...

Blog_photo
-14.05%
 risk: low
Expanded Sales Force Earns Pressure BioSciences, Inc. (PBIO) a “Speculative Strong Buy” Rating and Increased Sales  02/27/08
Dutton Associates recently rated Pressure BioSciences, Inc. (NASDAQ: PBIO) as a “Speculative Strong Buy,” pricing the 12-month target at $10 per share. The research report commends the company on its “unique and superior technology” applicable to a variety of areas in the life-sciences field. As Pressure BioSciences utilizes its expanded sales force, Dutton said it ex...

Blog_photo
-14.05%
 risk: low
Pressure Biosciences, Inc. (PBIO) Rolls Out New ProteoSolveLRS Kit to Battle Obesity  02/15/08
According to the most recent National Health and Nutrition Examination survey, roughly two-thirds of the adults in the United States are overweight, slowly closing the gap between themselves and the one-third of Americans considered obese. Analyzing the protein from lipid-rich tissues helps researchers understand the disease that kills about 300,000 people each year in the U.S. Additionally, obesit...


 


Discussion Wall + Add  

Blog_photo
quality stocks
Pressure Biosciences, Inc. (PBIO) Up Almost 8% afte.. - Pressure Biosciences, Inc. (PBIO) Up Almost 8% after Increased interest from Investors Who Attended the Red Chip Conference At the Red Chip conference...
+   1 reply

Blog_photo
quality stocks
QualityStocks.net Featured Companies - In this discussion we will present articles highlighting the companies we are currently featuring and believe to have the potential to grow rapidly in
+   87 replies


More Resources

Graphic_arrow1 About Pressure BioSciences Inc. - Answers.com

Graphic_arrow1 Historical Prices - Yahoo

Graphic_arrow1 Message Boards - BoardCentral.com

Graphic_arrow1 More Info:     Yahoo   |   Google   |   Reuters